GPI
RMD icon

General Partner Inc’s ResMed RMD Stock Holding History

General Partner Inc’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-291
Closed -$60.6K – 214
2022
Q4 		$60.6K Buy
+291
New +$63.9K 0.06% 119

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

General Partner Inc's RMD Position: Q1 2023 in Review

General Partner Inc sold out of ResMed (RMD) in Q1 2023, closing a stake of 291 shares — an estimated $60.6K sold.

General Partner Inc first reported a position in RMD in Q4 2022 and held it in 1 quarter. The position peaked at $60.6K in Q4 2022. 676 funds tracked by Wall St. Rank hold RMD as of Q1 2023.

  • General Partner Inc reported no remaining ResMed position as of Q1 2023 after selling out during the quarter.
  • General Partner Inc sold 291 ResMed shares in Q1 2023, an estimated $60.6K.
  • General Partner Inc first reported a position in ResMed in Q4 2022 and held it in 1 quarter.
  • General Partner Inc's ResMed position peaked at $60.6K in Q4 2022.
  • 676 funds tracked by Wall St. Rank held ResMed as of Q1 2023.

Based on General Partner Inc's 13F filing for Q1 2023, filed 7 Apr 2023.